Anebulo Pharmaceuticals (NASDAQ:ANEB) & Replimune Group (NASDAQ:REPL) Critical Comparison
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading Down 13.6% – What’s Next?
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Down 13.6% – What’s Next?
Anebulo Pharmaceuticals Announces Final Results of Tender Offer
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer
Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates
Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
Anebulo Pharmaceuticals Announces New CEO
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001
Is Anebulo Pharmaceuticals (ANEB) Outperforming Other Medical Stocks This Year?
Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year?
Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear
Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants
Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication
8 of the Hottest Cannabis Stocks Right Now
Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem
7 Pot Stocks That Lit Up the News Cycle This Week
CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials
A Week's Worth of Actionable Cannabis Stock News
U.S. IPO Weekly Recap: Sacramento Bank Five Star Bancorp Finishes On Top In An 8 IPO Week